Carmen Scheibenbogen: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
VisualWikitext
(added study and ref)
(links, new studies)
Line 19: Line 19:
*2015, Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome<ref name="Loebel, 2015" /> - [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0628-4 (Full Text)]
*2015, Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome<ref name="Loebel, 2015" /> - [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-015-0628-4 (Full Text)]
*2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with [[Chronic Fatigue Syndrome]]<ref name="Loebel, 2016" /> - [https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub (Full Text)]
*2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with [[Chronic Fatigue Syndrome]]<ref name="Loebel, 2016" /> - [https://www.sciencedirect.com/science/article/pii/S0889159115300209?via%3Dihub (Full Text)]
*2017, Serological profiling of the [[EBV]] immune response in [[Chronic Fatigue Syndrome]] using a peptide microarray<ref name="Loebel, 2017" /> -[http://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0179124 (Full Text)]
*2017, Serological profiling of the [[EBV]] immune response in [[Chronic Fatigue Syndrome]] using a peptide microarray<ref name="Loebel, 2017" /> - [http://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0179124 (Full Text)]
*2017, The European ME/CFS [[Biomarker]] Landscape project: an initiative of the European network EUROMENE<ref>{{Cite journal|last=Scheibenbogen|first=Carmen|author-link=Carmen Scheibenbogen|last2=Freitag|first2=Helma|author-link2=Helma Freitag|last3=Blanco|first3=Julià|author-link3=Julià Blanco|last4=Capelli|first4=Enrica|author-link4=Enrica Capelli|last5=Lacerda|first5=Eliana|author-link5=Eliana Lacerda|last6=Authier|first6=Jerome|author-link6=François Jérôme Authier|last7=Meeus|first7=Mira|author-link7=Mira Meeus|last8=Castro Marrero|first8=Jesus|author-link8=Jesús Castro-Marrero|last9=Nora-Krukle|first9=Zaiga|author-link9=Zaiga Nora-Krukle|last10=Oltra|first10=Elisa|author-link10=Elisa Oltra|last11= Strand|first11=Elin Bolle|author-link11=Elin Bolle Strand|last12= Shikova|first12= Evelina|author-link12= Evelina Shikova|last13= Sekulic|first13=Slobodan|author-link13=Slobodan Sekulic|last14=Murovska|first14=Modra|author-link14=Modra Murovska|date=2017-07-26|title=The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE|url=https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1263-z|journal=Journal of Translational Medicine|language=en|volume=15|issue=1|pages=|doi=10.1186/s12967-017-1263-z|issn=1479-5876|pmc=5530475|pmid=28747192|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530475/ (Full Text)]
*2017, The European ME/CFS [[Biomarker]] Landscape project: an initiative of the European network EUROMENE<ref>{{Cite journal|last=Scheibenbogen|first=Carmen|author-link=Carmen Scheibenbogen|last2=Freitag|first2=Helma|author-link2=Helma Freitag|last3=Blanco|first3=Julià|author-link3=Julià Blanco|last4=Capelli|first4=Enrica|author-link4=Enrica Capelli|last5=Lacerda|first5=Eliana|author-link5=Eliana Lacerda|last6=Authier|first6=Jerome|author-link6=François Jérôme Authier|last7=Meeus|first7=Mira|author-link7=Mira Meeus|last8=Castro Marrero|first8=Jesus|author-link8=Jesús Castro-Marrero|last9=Nora-Krukle|first9=Zaiga|author-link9=Zaiga Nora-Krukle|last10=Oltra|first10=Elisa|author-link10=Elisa Oltra|last11= Strand|first11=Elin Bolle|author-link11=Elin Bolle Strand|last12= Shikova|first12= Evelina|author-link12= Evelina Shikova|last13= Sekulic|first13=Slobodan|author-link13=Slobodan Sekulic|last14=Murovska|first14=Modra|author-link14=Modra Murovska|date=2017-07-26|title=The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE|url=https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1263-z|journal=Journal of Translational Medicine|language=en|volume=15|issue=1|pages=|doi=10.1186/s12967-017-1263-z|issn=1479-5876|pmc=5530475|pmid=28747192|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530475/ (Full Text)]
*2018, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an [[autoimmune disease]]<ref name="Sotzny, 2018" /> - [https://www.sciencedirect.com/science/article/pii/S1568997218300880 (Full Text)]
*2018, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an [[autoimmune disease]]<ref name="Sotzny, 2018" /> - [https://www.sciencedirect.com/science/article/pii/S1568997218300880 (Full Text)]
Line 26: Line 26:
* 2018, Prevalence and incidence of [[ME/CFS|myalgic encephalomyelitis/chronic fatigue syndrome]] in Europe—the Euro-epiME study from the European network [[EUROMENE]]: a protocol for a systematic review<ref>{{Cite journal|last=Estévez-López|first=Fernando|author-link=Fernando Estévez-López|last2=Castro-Marrero|first2=Jesus|author-link2=Jesús Castro-Marrero|last3=Wang|first3=Xia|author-link3=Xia Wang-Steverding|last4=Bakken|first4=Inger Johanne|author-link4=Inger Johanne Bakken|last5=Ivanovs|first5=Andrejs|author-link5=Andrejs Ivanovs|last6=Nacul|first6=Luis|author-link6=Luis Nacul|last7=Sepúlveda|first7=Nuno|author-link7=Nuno Sepulveda|last8=Strand|first8=Elin B.|author-link8=Elin Strand|last9=Pheby|first9=Derek|author-link9=Derek Pheby|last10=Alegre|first10=José|author-link10=José Alegre|last11=Scheibenbogen|first11=Carmen|author-link11=Carmen Scheibenbogen|last12=Shikova|first12=Evelina|author-link12=Evelina Shikova|last13=Lorusso|first13=Lorenzo|author-link13=Lorenzo Lorusso|last14=Capelli|first14=Enrica|author-link14=Enrica Capelli|last15=Sekulic|first15=Slobodan|author-link15=Slobodan Sekulic|last16=Lacerda|first16=Eliana|author-link16=Eliana Lacerda|last17=Murovska|first17=Modra|author-link17=Modra Murovska|date=2018-09-01|title=Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review|url=https://bmjopen.bmj.com/content/8/9/e020817|journal=BMJ Open|language=en|volume=8|issue=9|pages=e020817|doi=10.1136/bmjopen-2017-020817|issn=2044-6055|pmc=|pmid=30181183|via=}}</ref> - [https://bmjopen.bmj.com/content/8/9/e020817 (Full text)]
* 2018, Prevalence and incidence of [[ME/CFS|myalgic encephalomyelitis/chronic fatigue syndrome]] in Europe—the Euro-epiME study from the European network [[EUROMENE]]: a protocol for a systematic review<ref>{{Cite journal|last=Estévez-López|first=Fernando|author-link=Fernando Estévez-López|last2=Castro-Marrero|first2=Jesus|author-link2=Jesús Castro-Marrero|last3=Wang|first3=Xia|author-link3=Xia Wang-Steverding|last4=Bakken|first4=Inger Johanne|author-link4=Inger Johanne Bakken|last5=Ivanovs|first5=Andrejs|author-link5=Andrejs Ivanovs|last6=Nacul|first6=Luis|author-link6=Luis Nacul|last7=Sepúlveda|first7=Nuno|author-link7=Nuno Sepulveda|last8=Strand|first8=Elin B.|author-link8=Elin Strand|last9=Pheby|first9=Derek|author-link9=Derek Pheby|last10=Alegre|first10=José|author-link10=José Alegre|last11=Scheibenbogen|first11=Carmen|author-link11=Carmen Scheibenbogen|last12=Shikova|first12=Evelina|author-link12=Evelina Shikova|last13=Lorusso|first13=Lorenzo|author-link13=Lorenzo Lorusso|last14=Capelli|first14=Enrica|author-link14=Enrica Capelli|last15=Sekulic|first15=Slobodan|author-link15=Slobodan Sekulic|last16=Lacerda|first16=Eliana|author-link16=Eliana Lacerda|last17=Murovska|first17=Modra|author-link17=Modra Murovska|date=2018-09-01|title=Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review|url=https://bmjopen.bmj.com/content/8/9/e020817|journal=BMJ Open|language=en|volume=8|issue=9|pages=e020817|doi=10.1136/bmjopen-2017-020817|issn=2044-6055|pmc=|pmid=30181183|via=}}</ref> - [https://bmjopen.bmj.com/content/8/9/e020817 (Full text)]
*2018, Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)<ref>{{Cite journal|last=Rasa|first=Santa|author-link=Santa Rasa|last2=Nora-Krukle|first2=Zaiga|author-link2=Zaiga Nora-Krukle|last3=Henning|first3=Nina|author-link3=|last4=Eliassen|first4=Eva|author-link4=|last5=Shikova|first5=Evelina|author-link5=Evelina Shikova|last6=Harrer|first6=Thomas|author-link6=Thomas Harrer|last7=Scheibenbogen|first7=Carmen|author-link7=Carmen Scheibenbogen|last8=Murovska|first8=Modra|author-link8=Modra Murovska|last9=Prusty|first9=Bhupesh K.|author-link9=Bhupesh Prusty|last10=European Network on ME/CFS (EUROMENE)|first10=|author-link10=EUROMENE|date=2018-10-01|title=Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)|url=https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1644-y|journal=Journal of Translational Medicine|language=en|volume=16|issue=1|pages=|doi=10.1186/s12967-018-1644-y|issn=1479-5876|pmc=|pmid=30285773|quote=|via=}}</ref> - [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1644-y (Full text)]
*2018, Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)<ref>{{Cite journal|last=Rasa|first=Santa|author-link=Santa Rasa|last2=Nora-Krukle|first2=Zaiga|author-link2=Zaiga Nora-Krukle|last3=Henning|first3=Nina|author-link3=|last4=Eliassen|first4=Eva|author-link4=|last5=Shikova|first5=Evelina|author-link5=Evelina Shikova|last6=Harrer|first6=Thomas|author-link6=Thomas Harrer|last7=Scheibenbogen|first7=Carmen|author-link7=Carmen Scheibenbogen|last8=Murovska|first8=Modra|author-link8=Modra Murovska|last9=Prusty|first9=Bhupesh K.|author-link9=Bhupesh Prusty|last10=European Network on ME/CFS (EUROMENE)|first10=|author-link10=EUROMENE|date=2018-10-01|title=Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)|url=https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1644-y|journal=Journal of Translational Medicine|language=en|volume=16|issue=1|pages=|doi=10.1186/s12967-018-1644-y|issn=1479-5876|pmc=|pmid=30285773|quote=|via=}}</ref> - [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1644-y (Full text)]
*2019, Myalgic encephalomyelitis/chronic fatigue Syndrome (ME/CFS): Investigating care practices pointed out to disparities in diagnosis and treatment across European Union<ref name="Strand2019">https://doi.org/10.1371/journal.pone.0225995</ref> - [https://doi.org/10.1371/journal.pone.0225995 (Full text)]
*2020, IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS<ref name="IgG2020">{{Cite journal|last=Hartwig|first=Jelka|last2=Sotzny|first2=Franziska|last3=Bauer|first3=Sandra|last4=Heidecke|first4=Harald|last5=Riemekasten|first5=Gabriela|last6=Dragun|first6=Duska|last7=Meisel|first7=Christian|last8=Dames|first8=Claudia|last9=Grabowski|first9=Patricia|date=2020-03-01|title=IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS|url=http://www.sciencedirect.com/science/article/pii/S2666354620300120|journal=Brain, Behavior, & Immunity - Health|language=en|volume=3|pages=100047|doi=10.1016/j.bbih.2020.100047|issn=2666-3546}}</ref> - [https://www.sciencedirect.com/science/article/pii/S2666354620300120 (Full text)]
*2020, IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS<ref name="IgG2020">{{Cite journal|last=Hartwig|first=Jelka|last2=Sotzny|first2=Franziska|last3=Bauer|first3=Sandra|last4=Heidecke|first4=Harald|last5=Riemekasten|first5=Gabriela|last6=Dragun|first6=Duska|last7=Meisel|first7=Christian|last8=Dames|first8=Claudia|last9=Grabowski|first9=Patricia|date=2020-03-01|title=IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS|url=http://www.sciencedirect.com/science/article/pii/S2666354620300120|journal=Brain, Behavior, & Immunity - Health|language=en|volume=3|pages=100047|doi=10.1016/j.bbih.2020.100047|issn=2666-3546}}</ref> - [https://www.sciencedirect.com/science/article/pii/S2666354620300120 (Full text)]
*2020, Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome<ref name="Schreiner2020">{{Cite journal|last=Schreiner|first=Philipp|author-link=|last2=Harrer|first2=Thomas|author-link2=Thomas Harrer|last3=Scheibenbogen|first3=Carmen|author-link3=Carmen Scheibenbogen|last4=Lamer|first4=Stephanie|author-link4=|last5=Schlosser|first5=Andreas|author-link5=|last6=Naviaux|first6=Robert K.|author-link6=Robert Naviaux|last7=Prusty|first7=Bhupesh K.|author-link7=Bhupesh Prusty|last8=|first8=|date=2020-04-01|title=Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|url=https://www.immunohorizons.org/content/4/4/201|journal=ImmunoHorizons|language=en|volume=4|issue=4|pages=201–215|doi=10.4049/immunohorizons.2000006|issn=2573-7732|pmc=|pmid=32327453|access-date=|quote=|via=}}</ref> - [https://www.immunohorizons.org/content/4/4/201 (Full text)]
*2020, Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome<ref name="Schreiner2020">{{Cite journal|last=Schreiner|first=Philipp|author-link=|last2=Harrer|first2=Thomas|author-link2=Thomas Harrer|last3=Scheibenbogen|first3=Carmen|author-link3=Carmen Scheibenbogen|last4=Lamer|first4=Stephanie|author-link4=|last5=Schlosser|first5=Andreas|author-link5=|last6=Naviaux|first6=Robert K.|author-link6=Robert Naviaux|last7=Prusty|first7=Bhupesh K.|author-link7=Bhupesh Prusty|last8=|first8=|date=2020-04-01|title=Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|url=https://www.immunohorizons.org/content/4/4/201|journal=ImmunoHorizons|language=en|volume=4|issue=4|pages=201–215|doi=10.4049/immunohorizons.2000006|issn=2573-7732|pmc=|pmid=32327453|access-date=|quote=|via=}}</ref> - [https://www.immunohorizons.org/content/4/4/201 (Full text)]
* 2020, Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology <ref name="Estevez-Lopez2020">{{Cite journal|last=Estévez-López|first=Fernando|author-link=Fernando Estévez-López|last2=Mudie|first2=Kathleen|author-link2=|last3=Wang-Steverding|first3=Xia|author-link3=Xia Wang-Steverding|last4=Bakken|first4=Inger Johanne|author-link4=Inger Johanne Bakken|last5=Ivanovs|first5=Andrejs|author-link5=|last6=Castro-Marrero|first6=Jesús|author-link6=Jesús Castro-Marrero|last7=Nacul|first7=Luis|author-link7=Luis Nacul|last8=Alegre|first8=Jose|author-link8=José Alegre|last9=Zalewski|first9=Paweł|last10=Słomko|first10=Joanna|author-link10=|last11=Bolle Strand|first11=Elin|author-link11=Elin Bolle Strand|last12=Pheby|first12=Derek|author-link12=Derek Pheby|last13=Shikova|first13=Evelina|author-link13=Evelina Shikova|last14=Lorusso|first14=Lorenzo|author-link14=Lorenzo Lorusso|last15=Capelli|first15=Enrica|author-link15=Enrica Capelli|last16=Sekulic|first16=Slobodan|author-link16=Slobodan Sekulic|last17=Scheibenbogen|first17=Carmen|author-link17=Carmen Scheibenbogen|last18=Sepúlveda|first18=Nuno|author-link18=Nuno Sepúlveda|last19=Murovska|first19=Modra|author-link19=Modra Murovska|last20=Lacerda|first20=Eliana|author-link20=Eliana Lacerda|date=May 2020|title=Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology|url=https://www.mdpi.com/2077-0383/9/5/1557|journal=Journal of Clinical Medicine|language=en|volume=9|issue=5|pages=1557|doi=10.3390/jcm9051557|pmc=|pmid=|quote=|access-date=|via=}}</ref> - [https://www.mdpi.com/2077-0383/9/5/1557/htm (Full text)]
* 2020, Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology <ref name="Estevez-Lopez2020">{{Cite journal|last=Estévez-López|first=Fernando|author-link=Fernando Estévez-López|last2=Mudie|first2=Kathleen|author-link2=|last3=Wang-Steverding|first3=Xia|author-link3=Xia Wang-Steverding|last4=Bakken|first4=Inger Johanne|author-link4=Inger Johanne Bakken|last5=Ivanovs|first5=Andrejs|author-link5=|last6=Castro-Marrero|first6=Jesús|author-link6=Jesús Castro-Marrero|last7=Nacul|first7=Luis|author-link7=Luis Nacul|last8=Alegre|first8=Jose|author-link8=José Alegre|last9=Zalewski|first9=Paweł|last10=Słomko|first10=Joanna|author-link10=|last11=Bolle Strand|first11=Elin|author-link11=Elin Bolle Strand|last12=Pheby|first12=Derek|author-link12=Derek Pheby|last13=Shikova|first13=Evelina|author-link13=Evelina Shikova|last14=Lorusso|first14=Lorenzo|author-link14=Lorenzo Lorusso|last15=Capelli|first15=Enrica|author-link15=Enrica Capelli|last16=Sekulic|first16=Slobodan|author-link16=Slobodan Sekulic|last17=Scheibenbogen|first17=Carmen|author-link17=Carmen Scheibenbogen|last18=Sepúlveda|first18=Nuno|author-link18=Nuno Sepúlveda|last19=Murovska|first19=Modra|author-link19=Modra Murovska|last20=Lacerda|first20=Eliana|author-link20=Eliana Lacerda|date=May 2020|title=Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology|url=https://www.mdpi.com/2077-0383/9/5/1557|journal=Journal of Clinical Medicine|language=en|volume=9|issue=5|pages=1557|doi=10.3390/jcm9051557|pmc=|pmid=|quote=|access-date=|via=}}</ref> - [https://www.mdpi.com/2077-0383/9/5/1557/htm (Full text)]
* 2020, Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome<ref name=endothelial2020>{{Cite journal|last=Scherbakov|first=Nadja|author-link=|last2=Szklarski|first2=Marvin|author-link2=|last3=Hartwig|first3=Jelka|author-link3=|last4=Sotzny|first4=Franziska|author-link4=Franziska Sotzny|last5=Lorenz|first5=Sebastian|author-link5=|last6=Meyer|first6=Antje|author-link6=Antje Meyer|last7=Grabowski|first7=Patricia|last8=Doehner|first8=Wolfram|last9=Scheibenbogen|first9=Carmen|author-link9=Carmen Scheibenbogen|date=2020|title=Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12633|journal=ESC Heart Failure|language=en|volume=7|issue=3|pages=1064–1071|doi=10.1002/ehf2.12633|issn=2055-5822|pmc =  7261521|pmid=32154656|access-date=|quote=|via=}}</ref> - [https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12633 (Full text)]
* 2020, Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome<ref name=endothelial2020>{{Cite journal|last=Scherbakov|first=Nadja|author-link=|last2=Szklarski|first2=Marvin|author-link2=|last3=Hartwig|first3=Jelka|author-link3=|last4=Sotzny|first4=Franziska|author-link4=Franziska Sotzny|last5=Lorenz|first5=Sebastian|author-link5=|last6=Meyer|first6=Antje|author-link6=Antje Meyer|last7=Grabowski|first7=Patricia|last8=Doehner|first8=Wolfram|last9=Scheibenbogen|first9=Carmen|author-link9=Carmen Scheibenbogen|date=2020|title=Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12633|journal=ESC Heart Failure|language=en|volume=7|issue=3|pages=1064–1071|doi=10.1002/ehf2.12633|issn=2055-5822|pmc =  7261521|pmid=32154656|access-date=|quote=|via=}}</ref> - [https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.12633 (Full text)]
*2020, Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset<ref name="Steiner2021">https://www.frontiersin.org/articles/10.3389/fimmu.2020.00578/full</ref> - [https://www.frontiersin.org/articles/10.3389/fimmu.2020.00578/full (Full text)]
*2020, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption<ref name="Tolle2020">https://doi.org/10.3390/jcm9082443</ref> - [https://doi.org/10.3390/jcm9082443 (Full text)]
* 2021, The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies<ref>{{Cite journal|last=Malato|first=João|author-link=|last2=Sotzny|first2=Franziska|author-link2=Franziska Sotzny|last3=Bauer|first3=Sandra|author-link3=|last4=Freitag|first4=Helma|author-link4=|last5=Fonseca|first5=André|author-link5=|last6=Grabowska|first6=Anna D|author-link6=|last7=Graça|first7=Luís|last8=Cordeiro|first8=Clara|last9=Nacul|first9=Luís|author-link9=Luis Nacul|last10=Lacerda|first10=Eliana M|author-link10= Eliana Lacerda|last11=Castro-Marrero|first11=Jesus|author-link11=Jesus Castro-Marrero|last12=Scheibenbogen|first12=Carmen|author-link12=Carmen Scheibenbogen|last13=Westermeier|first13=Francisco|author-link13=|last14=Sepúlveda|first14=Nuno|author-link14=Nuno Sepúlveda|date=2021-03-24|title=The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies|url=http://medrxiv.org/lookup/doi/10.1101/2021.03.23.21254175|journal=medRxiv|language=en|volume=|issue=|pages=|doi=10.1101/2021.03.23.21254175|pmc=|pmid=33791744|access-date=|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010776/ (Full text)]
* 2021, The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies<ref>{{Cite journal|last=Malato|first=João|author-link=|last2=Sotzny|first2=Franziska|author-link2=Franziska Sotzny|last3=Bauer|first3=Sandra|author-link3=|last4=Freitag|first4=Helma|author-link4=|last5=Fonseca|first5=André|author-link5=|last6=Grabowska|first6=Anna D|author-link6=|last7=Graça|first7=Luís|last8=Cordeiro|first8=Clara|last9=Nacul|first9=Luís|author-link9=Luis Nacul|last10=Lacerda|first10=Eliana M|author-link10= Eliana Lacerda|last11=Castro-Marrero|first11=Jesus|author-link11=Jesus Castro-Marrero|last12=Scheibenbogen|first12=Carmen|author-link12=Carmen Scheibenbogen|last13=Westermeier|first13=Francisco|author-link13=|last14=Sepúlveda|first14=Nuno|author-link14=Nuno Sepúlveda|date=2021-03-24|title=The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies|url=http://medrxiv.org/lookup/doi/10.1101/2021.03.23.21254175|journal=medRxiv|language=en|volume=|issue=|pages=|doi=10.1101/2021.03.23.21254175|pmc=|pmid=33791744|access-date=|quote=|via=}}</ref> - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010776/ (Full text)]
*2020, A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors<ref name="Wirth2020a">https://doi.org/10.1016/j.autrev.2020.102527</ref> - [https://doi.org/10.1016/j.autrev.2020.102527 (Full text)]
*2021, Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)<ref name="Wirth2021a">https://doi.org/10.1186/s12967-021-02833-2</ref> - [https://doi.org/10.1186/s12967-021-02833-2 (Full text)]
*2021, European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe<ref name="Nacul2021">https://doi.org/10.3390/medicina57050510</ref> - [https://doi.org/10.3390/jcm10112420 (Full text)]
*2021, Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome<ref name="Freitag2021">https://www.mdpi.com/2077-0383/10/16/3675/htm</ref> - [https://www.mdpi.com/2077-0383/10/16/3675/htm (Full text)]
*2021, Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study<ref name="Scheibenbogen2021a">https://doi.org/10.3390/jcm10112420</ref> - [https://doi.org/10.3390/jcm10112420 (Full text)]
*2021, Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Germany<ref name="Froehlich2021">https://doi.org/10.3390/medicina57070646</ref> - [https://doi.org/10.3390/medicina57070646 (Full text)]


==Clinic location==
==Clinic location==
Line 37: Line 46:


==Talks and interviews==
==Talks and interviews==
 
*2021, [https://meassociation.org.uk/2021/09/iacfs-me-conference-professor-carmen-scheibenbogen-emerging-treatment-options-for-autoimmune-me-cfs/  Autoimmune ME/CFS Treatment Options] - IACFS/ME Conference
*2018, [https://cfc.charite.de/#c30485288 Talk "Chronic Fatigue Syndrome" for General Practitioners]  
*2018, [https://cfc.charite.de/#c30485288 Talk "Chronic Fatigue Syndrome" for General Practitioners]  
*2014, Speaker at the 9th [[Invest in ME International ME Conference]] [http://www.investinme.org/IIMEC9.shtml#dvd DVD available]
*2014, Speaker at the 9th [[Invest in ME International ME Conference]] [http://www.investinme.org/IIMEC9.shtml#dvd DVD available]


==Online presence==
==Online presence==
 
*[https://www.researchgate.net/profile/Carmen-Scheibenbogen Researchgate.net]
*[http://www.ncbi.nlm.nih.gov/pubmed/?term=Scheibenbogen%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26429318 PubMed]
*[http://www.ncbi.nlm.nih.gov/pubmed/?term=Scheibenbogen%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26429318 PubMed]
*[http://immunologie.charite.de/ Institute for Medical Immunology]
*[http://immunologie.charite.de/ Institute for Medical Immunology]
Line 48: Line 57:


==See also==
==See also==
*[[Invest in ME International ME Conference]]
*[[Invest in ME International ME Conference]]
*[[EUROMENE]]
*[[EUROMENE]]
*[[Charité Berlin]]
*[[Charité Berlin]]
*[[Solve ME/CFS Initiative]]


==Learn more==
==Learn more==
 
*[https://solvecfs.org/carmen-scheibenbogen/ Carmen Schiebenbogen] - Solve ME/CFS Initiative
*[https://solvecfs.org/carmen-scheibenbogen-2/ Carmen Schiebenbogen page 2] - Solve ME/CFS Initiative
*[http://www.euromene.eu/workinggroups/Biosketch2016Scheibenbogen.pdf Curriculum Vitae for EUROMENE]
*[http://www.euromene.eu/workinggroups/Biosketch2016Scheibenbogen.pdf Curriculum Vitae for EUROMENE]


Revision as of 13:45, November 25, 2021

Source:Invest in ME

Professor Doctor Carmen Scheibenbogen is an Internal Medicine physician, ME/CFS doctor and the Professor for Immunology and Deputy Chair, Institute of Medical Immunology, at the University Hospital Charité in Berlin, Germany. Her research focuses on the role of Epstein-Barr virus (EBV), particularly the characterization of EBV specific B cell and T cell response and the enhanced antibody response against EBV peptides in myalgic encephalomyelitis (ME) versus healthy controls.[1]

EUROMENE[edit | edit source]

Professor Scheibenbogen is the Leader of the Biomarkers Working Group of EUROMENE, a European Union, COST Action CA15111, not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[2]

Diagnostic test[edit | edit source]

Professor Scheibenbogen helped create the CellTrend Diagnostic Test which may help identify a subset of 20-30% of all patients with ME/CFS. These patients have elevated levels of three auto-antibodies, i.e., against the b2-adrenergic receptor, against the muscarinic cholinergic receptor 3 (M3) and against the muscarinic cholinergic receptor 4 (M4).[3]

Awards[edit | edit source]

Notable studies[edit | edit source]

  • 2014, Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome[6] - (Full Text)
  • 2015, Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome[7] - (Full Text)
  • 2015, Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome[8] - (Full Text)
  • 2016, Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome[9] - (Full Text)
  • 2017, Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray[10] - (Full Text)
  • 2017, The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE[11] - (Full Text)
  • 2018, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease[12] - (Full Text)
  • 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[13] - (Full Text)
  • 2018, The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome[14] - (Full Text)
  • 2018, Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review[15] - (Full text)
  • 2018, Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)[16] - (Full text)
  • 2019, Myalgic encephalomyelitis/chronic fatigue Syndrome (ME/CFS): Investigating care practices pointed out to disparities in diagnosis and treatment across European Union[17] - (Full text)
  • 2020, IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS[18] - (Full text)
  • 2020, Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[19] - (Full text)
  • 2020, Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology [20] - (Full text)
  • 2020, Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome[21] - (Full text)
  • 2020, Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset[22] - (Full text)
  • 2020, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption[23] - (Full text)
  • 2021, The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies[24] - (Full text)
  • 2020, A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors[25] - (Full text)
  • 2021, Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[26] - (Full text)
  • 2021, European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe[27] - (Full text)
  • 2021, Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[28] - (Full text)
  • 2021, Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study[29] - (Full text)
  • 2021, Medical Care Situation of People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Germany[30] - (Full text)

Clinic location[edit | edit source]

  • Charité University Medicine, Berlin, Germany

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ "Invest in ME Research - International ME Conferences and Colloquiums Home Page". investinme.org. Retrieved November 14, 2019.
  2. ↑ "Action CA15111". COST. Retrieved November 14, 2019.
  3. ↑ "POTS - CFS/ME - CRPS". CellTrend Luckenwalde. Retrieved February 18, 2020.
  4. ↑ "2016 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved November 14, 2019.
  5. ↑ "2017 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved November 14, 2019.
  6. ↑ Loebel, Madlen; Strohschein, Kristin; Giannini, Carolin; Koelsch, Uwe; Bauer, Sandra; Doebis, Cornelia; Thomas, Sybill; Unterwalder, Nadine; von Baehr, Volker; Reinke, Petra; Knops, Michael; Hanitsch, Leif G.; Meisel, Christian; Volk, Hans-Dieter; Scheibenbogen, Carmen (January 15, 2014), "Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome", PLoS One, doi:10.1371/journal.pone.0085387
  7. ↑ Guenther, Sabrina; Loebel, Madlen; Mooslechner, Agnes A; Knops, Michael; Hanitsch, Leif G; Grabowski, Patricia; Wittke, Kirsten; Meisel, Christian; Unterwalder, Nadine; Volk, Hans-Dieter; Scheibenbogen, Carmen (2015), "Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome", Human Immunology, 76 (10): 729-35, doi:10.1016/j.humimm.2015.09.028
  8. ↑ Loebel, Madlen; Mooslechner, Agnes Anna; Bauer, Sandra; Günther, Sabrina; Letsch, Anne; Hanitsch, Leif G; Grabowski, Patricia; Meisel, Christian; Volk, Hans-Dieter; Scheibenbogen, Carmen (2015), "Polymorphism in COMT is associated with IgG3 subclass level and susceptibility to infection in patients with chronic fatigue syndrome", Journal of Translational Medicine, 13, doi:10.1186/s12967-015-0628-4
  9. ↑ Loebel, M; Grabowski, P; Heidecke, H; Bauer, S; Hanitsch, LG; Wittke, K; Meisel, C; Reinke, P; Volk, H; Fluge, Ø; Mella, O; Scheibenbogen, C (2016), "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome", Brain, behavior, and immunity, 52: 32-39, doi:10.1016/j.bbi.2015.09.013
  10. ↑ Loebel, Madlen; Eckey, Maren; Sotzny, Franziska; Hahn, Elisabeth; Bauer, Sandra; Grabowski, Patricia; Zerweck, Johannes; Holenya, Pavlo; Hanitsch, Leif G.; Wittke, Kirsten; Borchmann, Peter; Rüffer, Jens-Ulrich; Hiepe, Falk; Ruprecht, Klemens; Behrends, Uta; Meindl, Carola; Volk, Hans-Dieter; Reimer, Ulf; Scheibenbogen, Carmen (2017), "Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray", PLOS ONE, 12 (6): e0179124, doi:10.1371/journal.pone.0179124
  11. ↑ Scheibenbogen, Carmen; Freitag, Helma; Blanco, Julià; Capelli, Enrica; Lacerda, Eliana; Authier, Jerome; Meeus, Mira; Castro Marrero, Jesus; Nora-Krukle, Zaiga; Oltra, Elisa; Strand, Elin Bolle; Shikova, Evelina; Sekulic, Slobodan; Murovska, Modra (July 26, 2017). "The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE". Journal of Translational Medicine. 15 (1). doi:10.1186/s12967-017-1263-z. ISSN 1479-5876. PMC 5530475. PMID 28747192.
  12. ↑ Sotzny, Franziska; Blanco, Julià; Capelli, Enrica; Castro-Marrero, Jesús; Steiner, Sophie; Murovska, Modra; Scheibenbogen, Carmen (2018), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease", Autoimmunity Reviews, doi:10.1016/j.autrev.2018.01.009
  13. ↑ Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald; Reinke, Petra; Volk, Hans-Dieter; Grabowski, Patricia (2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLoS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672.
  14. ↑ Yang, Chin-An; Bauer, Sandra; Ho, Yu-Chen; Sotzny, Franziska; Chang, Jan-Gowth; Scheibenbogen, Carmen (August 17, 2018). "The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome". Journal of Translational Medicine. 16 (1). doi:10.1186/s12967-018-1600-x. ISSN 1479-5876.
  15. ↑ Estévez-López, Fernando; Castro-Marrero, Jesus; Wang, Xia; Bakken, Inger Johanne; Ivanovs, Andrejs; Nacul, Luis; Sepúlveda, Nuno; Strand, Elin B.; Pheby, Derek; Alegre, José; Scheibenbogen, Carmen; Shikova, Evelina; Lorusso, Lorenzo; Capelli, Enrica; Sekulic, Slobodan; Lacerda, Eliana; Murovska, Modra (September 1, 2018). "Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review". BMJ Open. 8 (9): e020817. doi:10.1136/bmjopen-2017-020817. ISSN 2044-6055. PMID 30181183.
  16. ↑ Rasa, Santa; Nora-Krukle, Zaiga; Henning, Nina; Eliassen, Eva; Shikova, Evelina; Harrer, Thomas; Scheibenbogen, Carmen; Murovska, Modra; Prusty, Bhupesh K.; European Network on ME/CFS (EUROMENE) (October 1, 2018). "Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)". Journal of Translational Medicine. 16 (1). doi:10.1186/s12967-018-1644-y. ISSN 1479-5876. PMID 30285773.
  17. ↑ https://doi.org/10.1371/journal.pone.0225995
  18. ↑ Hartwig, Jelka; Sotzny, Franziska; Bauer, Sandra; Heidecke, Harald; Riemekasten, Gabriela; Dragun, Duska; Meisel, Christian; Dames, Claudia; Grabowski, Patricia (March 1, 2020). "IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS". Brain, Behavior, & Immunity - Health. 3: 100047. doi:10.1016/j.bbih.2020.100047. ISSN 2666-3546.
  19. ↑ Schreiner, Philipp; Harrer, Thomas; Scheibenbogen, Carmen; Lamer, Stephanie; Schlosser, Andreas; Naviaux, Robert K.; Prusty, Bhupesh K. (April 1, 2020). "Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". ImmunoHorizons. 4 (4): 201–215. doi:10.4049/immunohorizons.2000006. ISSN 2573-7732. PMID 32327453.
  20. ↑ Estévez-López, Fernando; Mudie, Kathleen; Wang-Steverding, Xia; Bakken, Inger Johanne; Ivanovs, Andrejs; Castro-Marrero, Jesús; Nacul, Luis; Alegre, Jose; Zalewski, Paweł; Słomko, Joanna; Bolle Strand, Elin; Pheby, Derek; Shikova, Evelina; Lorusso, Lorenzo; Capelli, Enrica; Sekulic, Slobodan; Scheibenbogen, Carmen; Sepúlveda, Nuno; Murovska, Modra; Lacerda, Eliana (May 2020). "Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology". Journal of Clinical Medicine. 9 (5): 1557. doi:10.3390/jcm9051557.
  21. ↑ Scherbakov, Nadja; Szklarski, Marvin; Hartwig, Jelka; Sotzny, Franziska; Lorenz, Sebastian; Meyer, Antje; Grabowski, Patricia; Doehner, Wolfram; Scheibenbogen, Carmen (2020). "Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome". ESC Heart Failure. 7 (3): 1064–1071. doi:10.1002/ehf2.12633. ISSN 2055-5822. PMC 7261521. PMID 32154656.
  22. ↑ https://www.frontiersin.org/articles/10.3389/fimmu.2020.00578/full
  23. ↑ https://doi.org/10.3390/jcm9082443
  24. ↑ Malato, João; Sotzny, Franziska; Bauer, Sandra; Freitag, Helma; Fonseca, André; Grabowska, Anna D; Graça, Luís; Cordeiro, Clara; Nacul, Luís; Lacerda, Eliana M; Castro-Marrero, Jesus; Scheibenbogen, Carmen; Westermeier, Francisco; Sepúlveda, Nuno (March 24, 2021). "The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies". medRxiv. doi:10.1101/2021.03.23.21254175. PMID 33791744.
  25. ↑ https://doi.org/10.1016/j.autrev.2020.102527
  26. ↑ https://doi.org/10.1186/s12967-021-02833-2
  27. ↑ https://doi.org/10.3390/medicina57050510
  28. ↑ https://www.mdpi.com/2077-0383/10/16/3675/htm
  29. ↑ https://doi.org/10.3390/jcm10112420
  30. ↑ https://doi.org/10.3390/medicina57070646

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

cholinergic Involving the neurotransmitter acetylcholine. Cholinergic side effects include diarrhea, blurred vision, decreased intraocular pressure, contricted pupil in the eyes, sweating, increased saliva and mucus on the lungs, bronchial constriction, increased gastrointestinal tone, decreased blood pressure, slow heart rate, and contraction of bladder detrusor muscle. muscle spasms/cramps, low blood pressure, slowed heart rate, nausea and vomiting, increased saliva and sweating, shortness of breath, and urinating more often.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

β β / Β. Greek letter beta (a symbol used in science), equivalent to "b".

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

mitochondria Important parts of the biological cell, with each mitochondrion encased within a mitochondrial membrane. Mitochondria are best known for their role in energy production, earning them the nickname "the powerhouse of the cell". Mitochondria also participate in the detection of threats and the response to these threats. One of the responses to threats orchestrated by mitochondria is apoptosis, a cell suicide program used by cells when the threat can not be eliminated.

enzyme a substance produced by a living organism which acts as a catalyst to bring about a specific biochemical reaction.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

BMJ The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

Retrieved from "https://me-pedia.org/w/index.php?title=Carmen_Scheibenbogen&oldid=94762"